Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.

Multiple sclerosis and related disorders·2026
Same author

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026
Same author

CSF turnover dysfunction: a hidden early biomarker in iRBD?

NPJ Parkinson's disease·2026
Same author

Long-Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection.

Annals of clinical and translational neurology·2026
Same author

Education Research: Moving Beyond "Outstanding": Neurology Program Directors' Perspectives on the MSPE Clerkship Summaries.

Neurology. Education·2026
Same author

The Prodromal Synucleinopathy Rating Scale: An Assessment in Patients With REM Sleep Behavior Disorder.

Neurology·2026

Related Experiment Video

Updated: Dec 23, 2025

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.0K

Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.

Farrah J Mateen1, Andre C Vogel2, Tamara B Kaplan3

  • 1Department of Neurology, Massachusetts General Hospital, 165 Cambridge St., Office 627, Boston, MA, 02114, USA. fmateen@mgh.harvard.edu.

Journal of Neurology
|April 26, 2020
PubMed
Summary

Bright white light therapy (BWLT) and dim red light therapy (DRLT) are safe and feasible for managing fatigue in multiple sclerosis (MS). Both light types showed improvements, suggesting a significant placebo effect in MS patients.

Keywords:
Clinical trialFatigueLight therapyMultiple sclerosisQuality of life

More Related Videos

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

662
Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

9.5K

Related Experiment Videos

Last Updated: Dec 23, 2025

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.0K
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

662
Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

9.5K

Area of Science:

  • Neurology
  • Therapeutics

Background:

  • Bright white light therapy (LT) is known to alleviate fatigue in various conditions.
  • Its efficacy and safety in multiple sclerosis (MS) patients remain uninvestigated.

Purpose of the Study:

  • To assess the feasibility, tolerability, and adherence of home-based LT for MS-associated fatigue.
  • To compare the effects of bright white LT versus dim red LT on fatigue and quality of life in MS.

Main Methods:

  • A 10-week randomized controlled trial involving adults with MS-associated fatigue.
  • Participants received either bright white LT (BWLT, 10,000 lx) or dim red LT (DRLT, <300 lx) for 1 hour twice daily.
  • A 2-week baseline, 4-week intervention, and 4-week washout period were implemented.

Main Results:

  • 35 participants were randomized (20 BWLT, 15 DRLT).
  • Both BWLT and DRLT groups showed significant reductions in fatigue severity (Fatigue Severity Scale scores) compared to baseline.
  • No significant differences in fatigue reduction or quality of life improvements were observed between the BWLT and DRLT groups.

Conclusions:

  • Home-based LT, including both bright white and dim red light, is safe, feasible, and well-tolerated in individuals with MS-associated fatigue.
  • The observed improvements in both groups suggest a substantial placebo effect associated with light therapy in this population.